Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP

Atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Clinically differentiating the thrombotic microangiopathies

(2013) Spero R. Cataland et al.   European Journal of Internal Medicine

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

(2013) C.M. Legendre et al.   NEW ENGLAND JOURNAL OF MEDICINE

Profound neurological injury in a patient with atypical hemolytic uremic syndrome

(2012) Galena Salem et al.   ANNALS OF HEMATOLOGY

The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies

(2012) Spero R. Cataland et al.   BRITISH JOURNAL OF HAEMATOLOGY

Complement activation in thrombotic thrombocytopenic purpura

(2012) M. RÉTI et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies

(2012) Julien Zuber et al.   Nature Reviews Nephrology

Advances in assay of complement function and activation

(2011) Morten Harboe et al.   ADVANCED DRUG DELIVERY REVIEWS

Platelet reactive conformation and multimeric pattern of von Willebrand factor in acquired thrombotic thrombocytopenic purpura during acute disease and remission

(2011) L. A. LOTTA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience

(2010) Paul Coppo et al.   PLoS One

Atypical Hemolytic–Uremic Syndrome

(2009) Marina Noris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

(2008) Ming Jin et al.   BRITISH JOURNAL OF HAEMATOLOGY